Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced hiv-infected children

Pediatric Infectious Disease Journal

Volumn 27, Issue 5, 2008, Pages 431-437

  Rudin, Christoph ^a   Burri, Marcus ^a   Shen, Yang ^b   Rode, Richard ^b   Nadal, David ^c  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b ABBOTT LABORATORIES   (United States)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

antiretroviral treatment; children; effectiveness; protease inhibitors; safety

Indexed keywords

AMPRENAVIR PHOSPHATE; ATAZANAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; LOPINAVIR; PYRIMIDINONE DERIVATIVE;

ADOLESCENT; ALLERGIC REACTION; AMYLASE BLOOD LEVEL; ARTICLE; CHILD; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IMMUNE RESPONSE; INFANT; LIPODYSTROPHY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; NEUTROPHIL COUNT; OBSERVATIONAL METHOD; PANCREATITIS; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE COUNT; VIRUS LOAD; VISUAL DISORDER; CD4 LYMPHOCYTE COUNT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LONGITUDINAL STUDY; NEWBORN; PREGNANCY; PRESCHOOL CHILD; SWITZERLAND; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIROLOGY;

ADOLESCENT; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; LONGITUDINAL STUDIES; MALE; NELFINAVIR; PREGNANCY; PYRIMIDINONES; RITONAVIR; SWITZERLAND; TREATMENT OUTCOME; VIRAL LOAD; WITHHOLDING TREATMENT;

EID: 45849102805     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181646d5a     Document Type: Article

References (19)

1. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infections. N Engl J Med. 1998;338:853- 860.
2. Sepkowitz K. AIDS-the first 20 years. N Engl J Med. 2001;344:1764-1772.
3. Sharland M, di Zub G, Ramos J, Blanche S, Gibb D. PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. HIV Med. 2002;3:215-226.
4. Wiznia A, Stanely K, Krogstad P, et al. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial-PACTG 377. AIDS Res Hum Retroviruses. 2000;16:1113-1121
5. Nadal D, Steiner F, Cheseaux J-J, et al; the Pediatric AIDS Group of Switzerland. Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Infection. 2000;28:287-296.
6. Nachman S, Stanley K, Yogev R, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children. A randomized controlled trial. JAMA. 2000;283:492- 498.
7. Soh CH, Oleske J, Brady M, et al. Long-term effects of proteaseinhibitor- based combination therapy on CD4 T-cell recovery in HIV-1- infected children and adolescents. Lancet. 2003;362:2045-2051.
8. The European Collaborative Study. Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life. Pediatrics 2001;108:116 -122.
9. Working Group on Antiretroviral Therapy and Medical Management of HIV-infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV. Available at: http://AIDSinfo.nih.gov. Accessed May 27, 2005.
10. PENTA Steering Committee. Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM, PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med. 2004;5(Suppl 2):61- 86.
11. Steiner F, Kind C, Aebi C, et al. Growth in human immunodeficiency virus type 1-infected children treated with protease inhibitors. Eur J Pediatr. 2001;160:611- 616.
12. Fairclough DL. Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC; 2002:125-128
13. de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA. 2000;284:190 -197.
14. Saez-Llorens S, Violari A, Deetz C, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003;22:216 -223.
15. Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet 2002; 359:733-740.
16. Funk M, Linde R, Wintergerst U, et al. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS. 1999;13: 1653-1658.
17. Gortmaker S, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528.
18. Yogev R, Lee S, Wiznia A, et al. Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human-immunodeficiency virus infection. Pediatr Infect Dis J. 2002;21:119 -125.
19. Resino S, Bellon J, Ramos J, et al. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study. J Antimicrob Chemother. 2004;54:921-931.